

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–767 and 731–TA–1750 (Final)]

L-Lysine from China; Cancellation of Hearing for Antidumping and Countervailing Duty Investigations

AGENCY: United States International Trade Commission.

ACTION: Notice.

DATES: July 10, 2026.

FOR FURTHER INFORMATION CONTACT: Caitlyn Costello (202–205–2058), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (<https://www.usitc.gov>). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION: On March 6, 2026, the Commission established a schedule for the final phase of the subject antidumping and countervailing duty investigations (91 FR 16967, April 3, 2026). On May 29, 2025, counsel for Lysine Fair Trade Coalition and its individual members (collectively, "Petitioners") filed a request to appear at the hearing. No other parties submitted a request to appear at the hearing. On July 9, 2026, counsel for the Petitioners withdrew their request to appear at the hearing, filed a request that the Commission cancel the scheduled hearing for this proceeding and indicated a willingness to respond to any Commission questions in lieu of

an actual hearing. The Commission considers Petitioners' letter to be a request under 19 CFR 201.12 to take action with respect to these investigations, and that cancellation is appropriate because a public hearing is not necessary to address the legal and factual issues these investigations present. Consequently, the Commission has cancelled the public hearing in connection with this proceeding, scheduled to begin at 9:30 a.m. on July 14, 2026. Parties to this proceeding should respond to any written questions posed by the Commission in their posthearing briefs, which are due to be filed on July 22, 2026.

For further information concerning this proceeding, see the Commission's notice cited above and the Commission's Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207).

Authority: This proceeding is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.21 of the Commission's rules.

By order of the Commission.

Issued: July 13, 2026.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2026–14277 Filed 7–15–26; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE**Drug Enforcement Administration**

[Docket No. DEA–1741]

Importer of Controlled Substances Application: Catalent Greenville, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Catalent Greenville, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY**

INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 17, 2026. Such persons may also file a written request for a hearing on the application on or before August 17, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on June 4, 2026, Catalent Greenville, Inc., 1240 Sugg Parkway, Greenville, North Carolina 27834–9006, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Lysergic acid diethylamide	7315	I
3,4-Methylenedioxymethamphetamine	7405	I
Psilocybin	7437	I

The company plans to import the listed controlled substances for dosage formulations development for research, clinical trial studies and analytical purposes. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-

approved finished dosage forms for commercial sale.

Thomas Prevoznik,

Deputy Assistant Administrator.

[FR Doc. 2026–14286 Filed 7–15–26; 8:45 am]

BILLING CODE 4410–09–P